Specifically, greater understanding of the SCLC molecular subgroup SCLC-N, with elevated NEUROD1 and low ASCL1, targeted by SVV-001 shed light on the mechanisms of viral entry and efficacy as well as possible future targets for SVV-001-derived therapies. The gene discussed is ASCL1; the disease is small cell lung carcinoma.